doxorubicin (LiPlasome)

N/A

Report date: 2025/10/27 17:55:41

Base Information

Drug Namedoxorubicin (LiPlasome)
Drug Alias Namedoxorubicindoxorubicin (LiPlasome)
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics > Anthracycline antibiotics
Mechanisms of ActionTopoisomerase II inhibitorsVirus DNA polymerase inhibitorsDNA intercalators
TargetsVirus DNA polymeraseDNATopoisomerase II
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryDenmark
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesLiPlasome Pharma ApS
China Registration ClassN/A

Develop Information

Active CompaniesLiPlasome Pharma ApS
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A